Recombinant Staphylococcus aureus Uridine kinase (udk)

What is the molecular structure of S. aureus UMPK and how does it differ from human UMPK?

S. aureus uridine monophosphate kinase (UMPK) exists as a homohexamer in solution with a molecular weight of approximately 150 kDa. Each monomeric unit has a molecular weight of 25 kDa as demonstrated by SDS-PAGE analysis . The quaternary structure is critical for its enzymatic function.

When comparing S. aureus UMPK with human UMPK (PDB ID: 1TEV) using structural alignment tools such as MATRAS, researchers observed an RMSD value of 4.24 Å, indicating significant structural differences between bacterial and human enzymes . This structural divergence is particularly important for drug development strategies, as it suggests potential selectivity of inhibitors that could target bacterial UMPK without affecting the human counterpart.

The structural differences include:

• Different oligomeric arrangements

• Unique binding pocket conformations

• Bacterial-specific regulatory domains

• Divergent substrate interaction sites

These structural variations provide substantial evidence for UMPK as a promising antimicrobial target with potentially reduced off-target effects on human enzymes.

What are the kinetic properties of S. aureus UMPK and how do they influence experimental design?

The enzyme kinetics of S. aureus UMPK reveal important properties that should inform experimental design in research settings. Key kinetic parameters include:

• Km value of 2.80 ± 0.1 μM, indicating high affinity for its substrate

• Vmax of 51.38 ± 1.39 μM of NADH/min/mg

• Cooperative kinetics with ATP as substrate

• Modulation by GTP, which decreases cooperativity and increases affinity for ATP

When designing experiments with recombinant S. aureus UMPK, researchers should consider:

• Optimal substrate concentrations: Due to the low Km value, experimental designs should include UMP concentrations that ensure substrate saturation (typically 10-15× Km).

• ATP concentration considerations: The cooperative kinetics with ATP means that reaction rates will not follow simple Michaelis-Menten kinetics. Researchers should use multiple ATP concentrations to characterize enzyme behavior fully.

• Effect of GTP: Including controlled amounts of GTP in reaction mixtures can modulate enzyme activity in predictable ways, potentially providing additional experimental controls.

• Buffer optimization: Reaction conditions should mirror those used in published characterizations (30 mM Tris-HCl, pH 7.5; 2 mM MgCl₂) to achieve comparable results .

These kinetic properties significantly impact experimental reproducibility and interpretation of results when working with recombinant S. aureus UMPK.

What are the optimal conditions for expressing recombinant S. aureus uridine kinase in E. coli systems?

Expression of recombinant S. aureus uridine kinase requires careful optimization to ensure high yield and proper folding. Based on established protocols, the following approach is recommended:

• Vector selection: The pQE30 vector system has been successfully employed for UMPK expression, providing an N-terminal His-tag for purification purposes . This system allows for IPTG-inducible expression under the control of the T5 promoter.

• Host strain selection:

  • E. coli DH5α has been validated for successful expression of S. aureus UMPK

  • Alternative strains like BL21(DE3) may offer improved expression for some researchers

  • Consider codon optimization if expression yields are low

• Culture conditions:

  • Growth temperature: 37°C for initial growth phase

  • Induction temperature: 25-30°C after induction to enhance proper folding

  • Media composition: LB medium supplemented with appropriate antibiotics

  • Induction parameters: 0.5-1.0 mM IPTG when culture reaches OD600 of 0.6-0.8

• Gene sequence considerations:

  • The UMPK gene sequence shows complete homology with the pyrH gene sequence across S. aureus strains

  • Accession number FJ415072 can be referenced for the complete gene sequence

When optimizing expression, researchers should monitor both total protein yield and specific enzyme activity to ensure that the recombinant protein maintains its native functional properties.

What purification methodology ensures optimal activity retention for recombinant S. aureus uridine kinase?

Purification of recombinant S. aureus uridine kinase requires a strategic approach to maintain enzyme integrity and maximize activity. The following methodological workflow has been validated:

• Initial capture:

  • Immobilized metal affinity chromatography (IMAC) using Ni-NTA resin for His-tagged proteins

  • Lysis buffer: 50 mM sodium phosphate, pH is critical (pH 8.0), 300 mM NaCl, 10 mM imidazole, and 1 mM PMSF

  • Washing: Gradual increase in imidazole concentration (20-40 mM) to remove non-specifically bound proteins

  • Elution: 250 mM imidazole in buffer matching lysis buffer composition

• Secondary purification:

  • Gel filtration chromatography on Sephadex G-200 has been demonstrated to effectively separate active hexameric UMPK (150 kDa) from aggregates and degradation products

  • Running buffer: 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5% glycerol

• Activity preservation considerations:

  • Include 1-5 mM DTT in all buffers to maintain reduced cysteines

  • Add 10% glycerol to final storage buffer to prevent freeze-thaw damage

  • Avoid multiple freeze-thaw cycles; aliquot purified enzyme

  • Activity assessments should be performed immediately after purification to establish baseline

• Quality control checkpoints:

  • SDS-PAGE should confirm 25 kDa monomeric form

  • Native PAGE or gel filtration should confirm the 150 kDa hexameric assembly

  • Specific activity measurement using standardized enzyme assays

  • Thermal stability profiling to ensure proper folding

The purified recombinant UMPK should demonstrate similar properties to the native enzyme, including comparable Km and Vmax values and response to regulatory molecules like GTP .

How can researchers accurately measure the activity of S. aureus uridine kinase in experimental settings?

Accurate measurement of S. aureus uridine kinase activity requires careful assay design and execution. The following methodological approaches have been validated:

• Coupled enzyme assay system:

  • The most common approach couples ADP production to NADH oxidation through pyruvate kinase and lactate dehydrogenase

  • This results in a decrease in absorbance at 340 nm that can be monitored continuously

  • Reaction components: UMP (substrate), ATP (phosphate donor), MgCl₂ (cofactor), phosphoenolpyruvate, NADH, pyruvate kinase, and lactate dehydrogenase

  • Standard conditions: 30 mM Tris-HCl (pH 7.5), 2 mM MgCl₂, optimal temperature of 37°C

• Direct product quantification:

  • HPLC-based methods can directly quantify UDP formation

  • Samples are quenched with EDTA at specific time points

  • Separation using anion exchange chromatography

  • UV detection at 254 nm for nucleotide quantification

• Radiometric assays:

  • Using [γ-³²P]ATP allows direct measurement of phosphate transfer

  • Reaction products are separated by thin-layer chromatography

  • Quantification via phosphorimaging provides high sensitivity

• Data analysis considerations:

  • Initial velocity conditions must be maintained (≤10% substrate conversion)

  • Controls for background ATP hydrolysis are essential

  • Enzyme concentration should be optimized to obtain linear rates

  • Cooperative kinetics with ATP requires appropriate mathematical models beyond Michaelis-Menten

When studying inhibition, researchers should consider:

• Preincubation of enzyme with inhibitor before substrate addition

• Varied inhibitor concentrations to establish Ki values

• Multiple substrate concentrations to determine mode of inhibition

Enzyme activity is typically expressed as μmol of NADH oxidized/min/mg protein, with reported Vmax values around 51.38 ± 1.39 μM of NADH/min/mg for the native enzyme .

What methodology should be used to evaluate inhibitors of S. aureus uridine kinase for antimicrobial development?

Evaluating inhibitors of S. aureus uridine kinase requires a systematic approach that integrates biochemical, structural, and cellular assessments. The following comprehensive methodology is recommended:

• Primary biochemical screening:

  • Initial screening at fixed inhibitor concentration (typically 10-100 μM)

  • Standard enzymatic assay using purified recombinant enzyme

  • Minimum 50% inhibition threshold for further investigation

  • Z-factor calculation to ensure assay quality (Z' > 0.5)

• Detailed inhibition kinetics:

  • Determination of Ki values through varied substrate and inhibitor concentrations

  • Analysis of inhibition modality (competitive, non-competitive, uncompetitive, mixed)

  • For reference, MMOXC inhibits UMPK with a Ki of 0.37 μmol/L

  • Special attention to cooperative ATP binding effects and allosteric regulation by GTP

• Structural basis of inhibition:

  • Molecular docking to predict binding modes

  • Comparison with human UMPK structures (RMSD 4.24 Å indicates structural difference)

  • Site-directed mutagenesis to confirm binding site predictions

  • X-ray crystallography or NMR studies of enzyme-inhibitor complexes when possible

• Cellular efficacy assessment:

  • Determination of MIC against S. aureus strains (reference: MMOXC showed MIC90 at 100 μmol/L)

  • Inclusion of clinical isolates and drug-resistant strains

  • Time-kill studies to determine bactericidal versus bacteriostatic effects

  • Combination studies with established antibiotics

• Mode of action confirmation:

  • Quantitative PCR to monitor gene expression changes (similar to analyses of MurF expression)

  • Metabolomic profiling to identify accumulation of pathway intermediates

  • Rescue experiments with pathway end-products

  • Transmission electron microscopy to observe cell wall morphology changes

• Anti-biofilm activity assessment:

  • Crystal violet staining to quantify biofilm formation inhibition

  • Confocal microscopy with live/dead staining

  • Testing against preformed biofilms (reference: MMOXC at 5 μmol/L completely removed preformed biofilms)

  • Flow cell systems for continuous biofilm monitoring

This methodical approach provides comprehensive data on inhibitor efficacy, specificity, and cellular effects, crucial for antimicrobial development targeting S. aureus uridine kinase.

How does S. aureus uridine kinase interact with other metabolic pathways during infection?

S. aureus uridine kinase functions as a critical node in bacterial metabolism, with complex interactions extending beyond its direct role in nucleotide synthesis. Understanding these interactions is crucial for comprehensive antimicrobial strategies:

• Interconnection with cell wall biosynthesis:

  • UMPK catalyzes the formation of UDP, which is a direct precursor for UDP-GlcNAc and UDP-MurNAc synthesis

  • These activated sugars are essential for peptidoglycan assembly

  • Inhibition of UMPK impacts MurF activity indirectly through precursor limitation

  • Studies demonstrate that compounds inhibiting UMPK (like MMOXC) also affect MurF function, with differential Ki values depending on the substrate: 0.3 μmol/L for UMT, 0.25 μmol/L for d-Ala-d-Ala, and 1.4 μmol/L for ATP

• Relationship with RNA biosynthesis and protein expression:

  • Pyrimidine nucleotide synthesis limitation affects transcription globally

  • Particular impact on highly expressed virulence factors

  • Transcriptome data reveals altered expression patterns in pyrimidine synthesis pathways following metabolic perturbations

  • Coordination with peptidyl deformylase (PDF) function, as both enzymes can be targeted by the same inhibitors

• Energy metabolism coordination:

  • ATP consumption by UMPK represents a significant energy investment

  • Allosteric regulation by GTP indicates integration with energy sensing

  • GTP decreases cooperativity of UMPK with ATP and increases affinity

  • This regulatory mechanism suggests coordination with bacterial stringent response

• Involvement in stress response and adaptation:

  • During infection, S. aureus must adapt to changing nutrient availability

  • UMPK activity influences adaptation to host environments

  • Connection with the serine/threonine kinase PknB regulatory network

  • Metabolic adaptation affects virulence factor expression and biofilm formation

These complex interactions make S. aureus uridine kinase a particularly valuable target for multi-effect antimicrobial strategies, as demonstrated by compounds like MMOXC that simultaneously inhibit cell wall synthesis, RNA biosynthesis, and protein maturation processes .

What methodological approaches can resolve contradictory data regarding S. aureus uridine kinase inhibition?

Researchers investigating S. aureus uridine kinase inhibition occasionally encounter contradictory experimental results. Resolving these discrepancies requires sophisticated methodological approaches:

• Standardization of enzyme preparation:

  • Verification of quaternary structure (hexameric form) by gel filtration

  • Consistent purification protocols across laboratories

  • Specific activity validation before inhibition studies

  • Assessment of batch-to-batch variability through reference inhibitors

• Comprehensive inhibition mechanism characterization:

  • Multi-substrate kinetic analysis using global fitting approaches

  • Evaluation of time-dependent inhibition phenomena

  • Testing for aggregation-based inhibition artifacts using detergent controls

  • Thermal shift assays to distinguish between specific binding and destabilization

• Advanced analytical approaches:

  • Isothermal titration calorimetry to directly measure binding energetics

  • Surface plasmon resonance for real-time binding kinetics

  • Mass spectrometry to identify covalent modifications or unexpected complexes

  • Hydrogen-deuterium exchange to map inhibitor-induced conformational changes

• Cellular context considerations:

  • Comparison between purified enzyme inhibition and whole-cell effects

  • Assessment of compound penetration using membrane permeability assays

  • Evaluation of efflux pump contributions to apparent resistance

  • Target engagement verification in intact cells

• Strain variability analysis:

  • Sequencing of UMPK/pyrH genes across clinical isolates

  • Expression level quantification in different strains

  • Activity assays with enzymes from multiple strains

  • Correlation of MIC values with genetic polymorphisms

• Interference elimination strategies:

  • Controls for inhibitor stability under assay conditions

  • Testing for interference with coupled assay components

  • Alternative assay methodologies to confirm results

  • Counterscreen against human UMPK to verify selectivity

How can researchers design experiments to evaluate the effect of uridine kinase inhibition on S. aureus virulence and infection dynamics?

Designing experiments to evaluate uridine kinase inhibition effects on S. aureus virulence requires a comprehensive approach spanning molecular, cellular, and in vivo techniques:

• Transcriptomic profiling approach:

  • RNA-seq analysis comparing inhibitor-treated and untreated S. aureus

  • Focus on virulence factor expression changes

  • Time-course studies to capture dynamic responses

  • qPCR validation of key virulence genes similar to MurF expression studies

  • Integration with existing S. aureus transcriptome datasets

• In vitro infection models:

  • Human cell line infection assays (e.g., macrophage models)

  • Assessment of bacterial adhesion, invasion, and intracellular survival

  • Cytotoxicity measurements following bacterial exposure

  • Specific protocols similar to those used for testing dCK inhibitors against S. aureus

  • Pre-treatment of bacteria with sub-MIC levels of inhibitors

• Biofilm evaluation methodology:

  • Crystal violet staining for quantitative assessment

  • Confocal microscopy with fluorescent markers for structural analysis

  • Testing against established biofilms at concentrations of 5 μmol/L (reference: MMOXC completely removed preformed biofilms)

  • Flow cell systems for continuous monitoring of biofilm development

• In vivo infection models design:

  • Mouse skin infection model (most relevant for S. aureus)

  • Systemic infection models for dissemination studies

  • Careful dosing strategies to achieve appropriate tissue concentrations

  • Bacterial burden quantification in tissues

  • Histopathological assessment of infection sites

  • Immune response characterization (cytokine profiling)

• Host-directed therapy considerations:

  • Parallel assessment of host enzyme inhibition (similar to dCK inhibitor studies)

  • Evaluation of host cell viability and function

  • Consideration of host metabolic pathways that may be affected

  • Combined approaches targeting both bacterial and host factors

• Resistance development assessment:

  • Serial passage experiments with sub-MIC inhibitor concentrations

  • Whole genome sequencing of resistant isolates

  • Biochemical characterization of enzymes from resistant strains

  • Fitness cost evaluation of resistance mechanisms

These experimental approaches allow researchers to comprehensively evaluate how uridine kinase inhibition affects the complex dynamics of S. aureus pathogenesis, while providing insights into potential therapeutic applications.

What are the key considerations when comparing different inhibitors of S. aureus uridine kinase pathway enzymes?

• Structural diversity and mechanism analysis:

  • Classification by chemical scaffold to identify structure-activity relationships

  • Binding mode determination (competitive, non-competitive, allosteric)

  • Reversibility assessment (reversible versus irreversible inhibition)

  • For example, MMOXC inhibits multiple targets with different Ki values: UMPK (0.37 μmol/L) and PDF (0.49 μmol/L)

• Comparative potency evaluation:

  • Standardized IC50 determination under identical conditions

  • Ki calculation accounting for substrate concentrations

  • Hill coefficients to detect cooperative inhibition

  • Residence time measurements (koff rates) for time-dependent inhibitors

  • Reference data: MMOXC showed IC50 in the range of 42 ± 1.5 to 50 ± 1 μmol/L against various S. aureus strains

• Target selectivity assessment:

  • Profiling against related bacterial kinases to assess specificity

  • Counter-screening against human orthologs (e.g., human UMPK, PDB ID: 1TEV)

  • Structural comparison data (RMSD 4.24 Å between human and S. aureus UMPK)

  • Activity against other enzymes in nucleotide synthesis pathways

• Comparative antimicrobial efficacy:

  • MIC90 determination across diverse clinical isolates

  • Time-kill kinetics comparison (bacteriostatic versus bactericidal)

  • Post-antibiotic effect duration

  • Anti-biofilm capability at defined concentrations

  • Reference: MMOXC demonstrated MIC90 at 100 μmol/L

• Physicochemical and pharmacological properties:

  • Solubility and stability in physiological conditions

  • Membrane permeability assessment

  • Protein binding evaluation

  • Metabolic stability and potential for drug-drug interactions

  • Formulation considerations for in vivo application

• Comparative table for multi-target inhibitors:

*MurF Ki varies with substrate: 0.3 μmol/L (UMT), 0.25 μmol/L (d-Ala-d-Ala), 1.4 μmol/L (ATP)

• Resistance potential comparison:

  • Frequency of resistance development

  • Cross-resistance patterns between different inhibitor classes

  • Genetic barriers to resistance

  • Fitness costs associated with resistance mechanisms

This structured comparative approach enables researchers to objectively evaluate different inhibitors targeting the S. aureus uridine kinase pathway, facilitating rational selection of lead compounds for further development.